Kevin Harley, MD
Nephrology · Orange, CANPI 1194924100
Payments from drug & device makers
Across 15 payments — averaging $27.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$126
- Amgen$84
- Otsuka America Pharmaceutical, Inc.$61
- Akebia Therapeutics Inc$25
- Recor Medical Inc$22
- Ardelyx, Inc.$20
- plus $71 from 4 others
What the payments were for
- Food & beverage$23156%
- Education$17844%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 3 | $126 |
| Amgen(2 entities) | 3 | $84 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Akebia Therapeutics Inc | 1 | $25 |
| Recor Medical Inc | 1 | $22 |
| Ardelyx, Inc. | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 2 | $18 |
| Fresenius USA Marketing, Inc. | 1 | $15 |
How this compares
$409 in reported general payments places this provider in the 30th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 46 | $69,838 |
| FarxigaDapagliflozin Propanediol | 25 | $19,982 |
| Sevelamer Carbonate | 31 | $16,744 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $12,949 |
| ProcritEpoetin Alfa | 16 | $12,022 |
| RetacritEpoetin Alfa-Epbx | 27 | $11,982 |
| Calcium Acetate | 26 | $5,438 |
| Calcitriol | 262 | $5,155 |
| Potassium Citrate ErPotassium Citrate | 35 | $3,560 |
| Midodrine Hcl | 45 | $2,954 |
| Tacrolimus | 15 | $1,564 |
| Bumetanide | 28 | $1,415 |
| Torsemide | 12 | $1,155 |
| Amlodipine Besylate | 142 | $945 |
| Nifedipine ErNifedipine | 19 | $882 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Orange
- Stephanie CheungOrange$1.1M
- Yasir QaziOrange$993K
- Ramy HannaOrange$923K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.